| Issue |
Section |
Title |
File |
| Vol 21, No 4 (2019) |
CLINICAL ONCOLOGY |
Possibilities of epigenetic therapy of acute myeloid leukemias in children |
(Rus)
|
| Vol 21, No 4 (2019) |
CLINICAL ONCOLOGY |
Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Ifosfamide/cyclofosfamide-induced methemoglobinemia in pediatric patients with hemoblastoses |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Detection and monitoring of minimal residual disease in acute megakaryoblastic leukemia in children |
(Rus)
|
| Vol 23, No 4 (2021) |
CLINICAL ONCOLOGY |
Role of pharmacogenetic factors in the development of side effects of methotrexate in the treatment of malignant tumors: A review |
(Rus)
|
| Vol 24, No 3 (2022) |
CLINICAL ONCOLOGY |
Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience |
(Rus)
|
| Vol 25, No 1 (2023) |
CLINICAL ONCOLOGY |
Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results |
(Rus)
|
| Vol 25, No 1 (2023) |
CLINICAL ONCOLOGY |
The role of minimal residual disease in therapy of pediatric acute lymphoblastic leukemia: a prospective cohort study |
(Rus)
|
| Vol 25, No 3 (2023) |
CLINICAL ONCOLOGY |
International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review) |
(Rus)
|
| Vol 26, No 3 (2024) |
Articles |
Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Experience of like-SJMB03 protocolin treatment of children with medulloblastomain the age group over 3 years:results of an intercenter pilot study |
(Rus)
|
